• Je něco špatně v tomto záznamu ?

Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma

E. Laukhtina, B. Pradere, D. D'Andrea, G. Rosiello, S. Luzzago, A. Pecoraro, C. Palumbo, S. Knipper, PI. Karakiewicz, V. Margulis, F. Quhal, RS. Motlagh, H. Mostafaei, K. Mori, VM. Schuettfort, D. Enikeev, SF. Shariat

. 2021 ; 10 (2) : 609-619. [pub] -

Jazyk angličtina Země Čína

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21010563

Background: Accurate identification of ideal candidates for cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) is an unmet need. We tested the association between preoperative value of systemic albumin to globulin ratio (AGR) and overall survival (OS) as well as cancer-specific survival (CSS) in mRCC patients treated with CN. Methods: mRCC patients treated with CN were included. The overall population was therefore divided into two AGR groups using cut-off of 1.43 (low, <1.43 vs. high, ≥1.43). Univariable and multivariable Cox regression analyses tested the association between AGR and OS as well as CSS. The discrimination of the model was evaluated with the Harrel's concordance index (C-index). The clinical value of the AGR was evaluated with decision curve analysis (DCA). Results: Among 613 mRCC patients, 159 (26%) patients had an AGR <1.43. Median follow-up was 31 (IQR: 16-58) months. On univariable analysis, low preoperative serum AGR was significantly associated with both OS (HR: 1.55, 95% CI: 1.26-1.89, P<0.001) and CSS (HR: 1.55, 95% CI: 1.27-1.90, P<0.001). On multivariable analysis, AGR <1.43 was associated with worse OS (HR: 1.51, 95% CI: 1.23-1.85, P<0.001) and CSS (HR: 1.52, 95% CI: 1.24-1.86, P<0.001). The addition of AGR only minimally improved the discrimination of a base model that included established clinicopathologic features (C-index=0.640 vs. C-index=0.629). On DCA, the inclusion of AGR marginally improved the net benefit of the prognostic model. Low AGR remained independently associated with OS and CSS in the IMDC intermediate risk group (HR: 1.52, 95% CI: 1.16-1.99, P=0.002). Conclusions: In our study, low AGR before CN was associated with worse OS and CSS, particularly in intermediate risk patients.

Cancer Prognostics and Health Outcomes Unit Division of Urology University of Montreal Health Center Montreal Canada

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology and Division of Experimental Oncology Urological Research Institute IRCCS San Raffaele Scientific Institute Milan Italy

Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria

Department of Urology European Institute of Oncology IRCCS Milan Italy

Department of Urology King Fahad Specialist Hospital Dammam Saudi Arabia

Department of Urology San Luigi Gonzaga Hospital University of Turin Turin Italy

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology University Hospital of Tours Tours France

Department of Urology University Medical Center Hamburg Eppendorf Hamburg Germany

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Weill Cornell Medical College New York NY USA

Division of Urology Department of Special Surgery Jordan University Hospital The University of Jordan Amman Jordan

European Association of Urology Research Foundation Arnhem The Netherlands

Institute for Urology and Reproductive Health Sechenov University Moscow Russia

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

Martini Klinik Prostate Cancer Center University Hospital Hamburg Eppendorf Hamburg Germany

Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz Iran

Urology Unit Department of Medical and Surgical Specialties ASST Spedali Civili of Brescia Radiological Science and Public Health University of Brescia Brescia Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010563
003      
CZ-PrNML
005      
20210715153931.0
007      
ta
008      
210413s2021 cc f 000 0|eng||
009      
AR
024    7_
$a 10.21037/tau-20-1101 $2 doi
035    __
$a (PubMed)33718063
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a cc
100    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
245    10
$a Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma / $c E. Laukhtina, B. Pradere, D. D'Andrea, G. Rosiello, S. Luzzago, A. Pecoraro, C. Palumbo, S. Knipper, PI. Karakiewicz, V. Margulis, F. Quhal, RS. Motlagh, H. Mostafaei, K. Mori, VM. Schuettfort, D. Enikeev, SF. Shariat
520    9_
$a Background: Accurate identification of ideal candidates for cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) is an unmet need. We tested the association between preoperative value of systemic albumin to globulin ratio (AGR) and overall survival (OS) as well as cancer-specific survival (CSS) in mRCC patients treated with CN. Methods: mRCC patients treated with CN were included. The overall population was therefore divided into two AGR groups using cut-off of 1.43 (low, <1.43 vs. high, ≥1.43). Univariable and multivariable Cox regression analyses tested the association between AGR and OS as well as CSS. The discrimination of the model was evaluated with the Harrel's concordance index (C-index). The clinical value of the AGR was evaluated with decision curve analysis (DCA). Results: Among 613 mRCC patients, 159 (26%) patients had an AGR <1.43. Median follow-up was 31 (IQR: 16-58) months. On univariable analysis, low preoperative serum AGR was significantly associated with both OS (HR: 1.55, 95% CI: 1.26-1.89, P<0.001) and CSS (HR: 1.55, 95% CI: 1.27-1.90, P<0.001). On multivariable analysis, AGR <1.43 was associated with worse OS (HR: 1.51, 95% CI: 1.23-1.85, P<0.001) and CSS (HR: 1.52, 95% CI: 1.24-1.86, P<0.001). The addition of AGR only minimally improved the discrimination of a base model that included established clinicopathologic features (C-index=0.640 vs. C-index=0.629). On DCA, the inclusion of AGR marginally improved the net benefit of the prognostic model. Low AGR remained independently associated with OS and CSS in the IMDC intermediate risk group (HR: 1.52, 95% CI: 1.16-1.99, P=0.002). Conclusions: In our study, low AGR before CN was associated with worse OS and CSS, particularly in intermediate risk patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Department of Urology, University Hospital of Tours, Tours, France
700    1_
$a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Rosiello, Giuseppe $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada ; Department of Urology and Division of Experimental Oncology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Luzzago, Stefano $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada ; Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy
700    1_
$a Pecoraro, Angela $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada ; Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy
700    1_
$a Palumbo, Carlotta $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada ; Urology Unit, Department of Medical and Surgical Specialties, ASST Spedali Civili of Brescia, Radiological Science and Public Health, University of Brescia, Brescia, Italy
700    1_
$a Knipper, Sophie $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada ; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada
700    1_
$a Margulis, Vitaly $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
700    1_
$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia
700    1_
$a Motlagh, Reza Sari $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
700    1_
$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Enikeev, Dmitry $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria ; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia ; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA ; Department of Urology, Weill Cornell Medical College, New York, NY, USA ; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic ; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria ; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan ; European Association of Urology Research Foundation, Arnhem, The Netherlands
773    0_
$w MED00201296 $t Translational andrology and urology $x 2223-4691 $g Roč. 10, č. 2 (2021), s. 609-619
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33718063 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210715153930 $b ABA008
999    __
$a ind $b bmc $g 1649859 $s 1130939
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 10 $c 2 $d 609-619 $e - $i 2223-4691 $m Translational andrology and urology $n Transl Androl Urol $x MED00201296
LZP    __
$a Pubmed-20210413

Najít záznam

Citační ukazatele

Možnosti archivace